Compare VERI & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERI | PLX |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.0M | 159.5M |
| IPO Year | 2017 | 1996 |
| Metric | VERI | PLX |
|---|---|---|
| Price | $1.86 | $1.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $7.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 3.0M | 856.2K |
| Earning Date | 04-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | ★ $92,637,000.00 | $52,744,000.00 |
| Revenue This Year | $52.20 | $36.81 |
| Revenue Next Year | $3.06 | N/A |
| P/E Ratio | ★ N/A | $8.91 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.29 | $1.34 |
| 52 Week High | $9.42 | $3.19 |
| Indicator | VERI | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 39.70 | 40.38 |
| Support Level | $1.63 | $1.87 |
| Resistance Level | $2.35 | $2.16 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 3.09 | 27.87 |
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has presence in the United States, the United Kingdom, France, Australia, Israel, and India.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.